Transforming growth factor-β levels in human allograft chronic fibrosis correlate with rate of decline in renal function

Transplantation

Volumn 68, Issue 6, 1999, Pages 785-790

  Cuhaci, Bulent ^a   Kumar, Mysore S A ^a   Bloom, Roy D ^d   Pratt, Bruce ^f   Haussman, Gail ^c   Laskow, David A ^e   Alidoost, Moona ^a   Grotkowski, Carolyn ^b   Cahill, Kathy ^e   Butani, Lavjay ^b   Sturgill, Benjamin C ^c   Pankewycz, Oleh G ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Robert Wood Johnson University   (United States)

^f GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; PRIORITY JOURNAL; SCAR FORMATION;

ADULT; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033610246     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199909270-00010     Document Type: Article

References (48)

1. Paul LC. Chronic renal transplant loss. Kidney Int 1995; 47: 1491.
2. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.
3. The Canadian Multicenter Transplant Study Group: a randomized trial of cyclosporin in cadaveric renal transplantation. N Engl J Med 1983; 309: 809.
4. European Multicenter Trial Group: Cyclosporin in cadaveric renal transplantation: one year follow-up of a multicenter trial. Lancet 1983; 2: 986.
5. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-Receptor blockade with Daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
6. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
7. Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. One-year follow-up from an open label trial of FK506 in primary kidney transplantation: a report of the U.S. Multicenter FK506 Kidney Transplantation Group. Transplantation 1996; 61: 1576.
8. Kahan BD. Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 1997; 29: 48.
9. Almond PS, Matas A, Gillingham KJ, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752.
10. Yilmaz S, Hayry P. The impact of acute episodes of rejection on the generation of chronic rejection in rat renal allografts. Transplantation 1993; 56: 1153.
11. Ferguson R. Acute rejection episodes - best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994; 328.
12. Cecka JM. Terasaki PI. The UNOS scientific renal transplant registry. United network for organ sharing. Clin Transplant 1994; 1: 18.
13. Bia MJ. Nonimmunologic causes of late renal graft loss. Kidney Int 1995; 47: 1491.
14. Kasiske BL, Kalil RSN, Lee HS, Rao KV. Histopathologic findings associated with chronic, progressive decline in renal allograft function. Kidney Int 1991; 40: 514.
15. Solez K, Axelsen RA, Benediktsson H, et. al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Inter. 1993; 44: 411.
16. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313.
17. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699.
18. Shibab FS. Cyclosporine nephropathy: pathophysiology and clinical impact. Semin Nephrol 1996; 16: 536.
19. Mihatsch MJ, Thiel G, Basler V, et. al. Morphological patterns in cylosporin treated renal transplant recipients. Transplant Proc 1985; 17 (Suppl 1): S101.
20. Palestine AG, Nussenblat RB, Chan C-C. Side effects of systemic cyclosporin in patients not undergoing transplantation. Am J Med 1984; 77: 652.
21. Myers BD, Sibley R, Newton L, et. al. The long-term course of cyclosporine associated chronic nephropathy. Kidney Int 1988; 33: 590.
22. Khanna A, Kapur S, Sharma V, Li B, Suthanthiran M. In vivo hyperexpression of transforming growth factor - β1 in mice: Stimulation by cyclosporine. Transplantation 1997; 63: 1037.
23. Shin G-T, Khanna A, Ding R, et al. In vivo expression of transforming growth factor - β1 in humans: Transplantation 1998; 65: 313.
24. Prashar Y, Khanna A, Sehajpal P, Sharma VK, Suthanthiran M. Stimulation of transforming growth factor-β1 transcription by cyclosporin. FEBS Lett 1995; 358: 109.
25. Shehata M, Cope GH, Johnson TS, Raftery AT, El Nahas AM Cyclosporine enhances the expression of TGF-β in the juxtaglomerular cells of the rat kidney. Kidney Intern 1995; 48: 1487.
26. Wolf G, Thaiss F, Stahl RA. Cyclosporin stimulates expression of transforming growth factor-β in renal cells. Transplantation 1995; 60: 237.
27. Shibab FS, Andoh TF, Tanner AM, et. al. Role of transforming growth factor - β1 in experimental chronic cyclosporin nephropathy. Kidney Intern 1996; 49: 1141.
28. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286.
29. Border WA, Ruoslahti E. Transforming growth factor-β in disease: the dark side of tissue repair. J Clin Invest 1992; 90: 1.
30. Shihab FS. Yamamoto T. Nast CC, et. al. Transforming growth factor - β and matrix protein expression in acute and chronic rejection in human renal allografts. J Am Soc Nephrol 1995; 6: 286.
31. Coupes BM, Newstead CG, Short CD, Brenchley PEC. Transforming growth factor-β1 in renal allograft recipients. Transplantation 1994; 57: 1727.
32. Sharma VK, Bologa RM, Xu G-P, et al. Intragraft TGF-β1 mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996; 49: 1297.
33. Gaciong Z, Koziak K, Religa P, et al. Increased expression of growth factors during chronic rejection of human kidney allograft. Transplantation Proc 1995; 27: 928.
34. Shibab FS, Tanner Am, Shao Y, Weffer MI. Expression of TGF-β1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996; 50: 1904.
35. Paul LC, Saito K, Davidoff A, Benediktsson H. Growth factor transcripts in rat renal transplants. Am J Kidney Dis 1996; 28: 441.
36. Vuillemin T, Legendre C, Meduri G, et. al. In situ expression of cell growth factors in human renal chronic graft rejection. Transplant Proc 1996; 29: 1513.
37. Horvath LZ, Friess H, Schilling M, et al. Altered expression of transforming growth factor - βs in chronic renal rejection. Kidney Int 1996; 50: 489.
38. Lantz I, Dimeny E, Larsson E, Fellstrom B, Funa K. Increased immunoreactivity of transforming growth factor - β in human kidney transplants. Transplant Immunol 1996; 4: 209.
39. Suthanthiran M: Clinical application of molecular biology: a study of allograft rejection with polymerase chain reaction. Am J Med Sci 313:264-267, 1997.
40. Suthanthiran M. Molecular analyses of human renal allografts: differential intragraft gene expression during rejection. Kidney Int 1997; 51(S58): S15.
41. Pankewycz OG, Miao L, Isaacs R, et al. Increased renal tubular expression of transforming growth factor -beta in human allografts correlates with cyclosporin toxicity. Kidney Int 1996; 50: 1634.
42. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-β. J Immunol 1989; 142: 1536.
43. Tilney NL, Whitley WD, Diamond JR, Kupiec-Weglinski JW, Adams DH. Chronic rejection - an undefined conundrum. Transplantation 1991; 52: 389.
44. Ahuja SS, Shrivastav S, Danielpour D, Balow JE, Boumpas DT. Regulation of transforming growth factor - β1 and its receptor by cyclosporin in human T lymphocytes. Transplantation 1995; 60: 718.
45. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-β1 gene. Transplantation 1998; 66: 1014.
46. Rush DN, Jeffery JR, Gough J Sequential protocol biopsies in renal transplant patients. Transplantation 1995; 59: 511.
47. Swain SL, Huston G, Tonkonogy S, Weinberg A. Transforming growth factor-β and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J Immunol 1991; 147: 2991.
48. Nickerson P, Jeffery J, Gough J, et al. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol 1998; 9: 482.